{"organizations": ["GlaxoSmithKline"], "uuid": "e215256b811678cffdfde512dca770a921380988", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.finance.yahoo.com", "main_image": "https://s.yimg.com/bt/api/res/1.2/6rik6AZwuPGCiADf_9dhPQ--/YXBwaWQ9eW5ld3M7cT03NTt3PTYwMA--/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://uk.finance.yahoo.com/news/provider-reuters/?format=rss", "section_title": "Finance News | Reuters - Yahoo! UK & Ireland Finance", "url": "https://uk.finance.yahoo.com/news/glaxosmithkline-second-quarter-beats-despite-112048833.html", "country": "GB", "title": "GlaxoSmithKline second-quarter beats despite Advair hit, lower margins", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "GlaxoSmithKline second-quarter beats despite Advair hit, lower margins", "spam_score": 0.0, "site_type": "news", "published": "2015-07-29T14:20:00.000+03:00", "replies_count": 0, "uuid": "e215256b811678cffdfde512dca770a921380988"}, "author": "", "url": "https://uk.finance.yahoo.com/news/glaxosmithkline-second-quarter-beats-despite-112048833.html", "ord_in_thread": 0, "title": "GlaxoSmithKline second-quarter beats despite Advair hit, lower margins", "locations": ["Advair"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "99.90 +1.05 \nLONDON (Reuters) - A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline (GSK.L) in the second quarter, although core earnings per share fell by a less-than-expected 9 percent. \nThe drugmaker recently sold its marketed cancer drugs to Novartis (NOVN.VX) and bought the Swiss group's vaccines, while increasing its consumer health business through a joint venture. \nThe revamp is designed to ensure sustainable growth, after past profit misses, but the strategy will take time to pay off and GSK on Wednesday reiterated its forecast for a high-teens percentage decline in 2015 earnings, at constant exchange rates. \nIn sterling terms, sales rose 6 percent to 5.9 billion pounds ($9.2 billion), reflecting the first full quarter that included products previously owned by Novartis. \nCore earnings fell to 17.3 pence a share, however, because of lower returns on Advair and the fact GSK has swapped high-margin cancer drugs for less profitable consumer products. \nAnalysts, on average, had forecast sales of 5.9 billion pounds and core EPS, which excludes certain items, of 16.7p, according to Thomson Reuters. \n(Reporting by Ben Hirschler; Editing by Martinne Geller)", "external_links": [], "published": "2015-07-29T14:20:00.000+03:00", "crawled": "2015-07-29T14:31:35.137+03:00", "highlightTitle": ""}